Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Noxopharm SOF-VAC asset 'markedly' reduces mRNA vaccine-related inflammation, study shows

Published 18/10/2023, 09:20 am
Updated 18/10/2023, 09:30 am
© Reuters.  Noxopharm SOF-VAC asset 'markedly' reduces mRNA vaccine-related inflammation, study shows

Noxopharm Ltd (ASX:NOX, OTC:NOXOF) has fielded new data illustrating that its mRNA vaccine enhancer, SOF-VAC™, markedly reduces mRNA-induced inflammation in an animal model.

The implications of these findings are far-reaching.

While mRNA vaccines have revolutionised the treatment of infectious diseases, their uptake has been marred by concerns over side effects, primarily due to inflammation and associated side effects. This was widely seen during the mRNA vaccine rollout in the wake of the COVID-19 pandemic.

Solution of major importance

SOF-VAC™ offers a promising solution to this challenge, thereby potentially expanding the utility and acceptance of mRNA vaccines.

Noxopharm CEO Dr Gisela Mautner said: “Our results are a significant milestone in the development of SOF-VAC. They show that it works in reducing inflammation, which should translate into fewer side effects from mRNA vaccines.

“This is of major importance as vaccines are given to populations that are essentially healthy, and who do not want to be negatively affected by a preventative vaccine administration.

“We have now taken SOF-VAC to the point where we consider the data is strong enough for it to be of interest to other companies, and so are stepping up our efforts to find the right partner to continue its clinical development.”

Developed in partnership with Melbourne's Hudson Institute of Medical Research, SOF-VAC was engineered to mitigate inflammatory responses when administered alongside mRNA vaccines.

Fully compatible with existing delivery platforms

It is fully compatible with existing mRNA vaccine delivery platforms and operates by blocking specific inflammation receptors in the body.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The research shows that fragments of mRNA stimulate inflammation receptors, leading to inflammation and other vaccine-related side effects.

When SOF-VAC is introduced along with an mRNA vaccine, it effectively blocks these receptors, reducing adverse effects.

In recent animal trials, the addition of SOF-VAC led to around a 50% decrease in inflammation when compared to the administration of mRNA alone.

The comprehensive data package suggests a highly significant drop in the levels of nine inflammatory biomarkers.

Importantly, the data also confirms that the effectiveness of the RNA remains high, a critical factor for vaccines aiming to combat various infectious diseases.

This makes SOF-VAC not just an enhancer but potentially a vital component in increasing vaccine tolerance among broader demographics.

Commercial partnerships sought

Having achieved a comprehensive data package, Noxopharm is actively seeking commercial partnerships to advance SOF-VAC to the next development phase.

This could herald a transformative moment for the biotech company and perhaps for the future of mRNA vaccines on a global scale.

Hudson Institute associate professor Michael Gantier said: “The development of RNA-based therapeutics is one of the most exciting areas of medicine, and these results are the outcome of many years of research.

“Our demonstration that molecules as short as SOF-VAC can have such targeted anti-inflammatory effects is genuinely novel, and gives SOF-VAC an advantage for use not only in vaccines but also in the many RNA-based drugs we see coming down the pipeline.”

Read more on Proactive Investors AU

Disclaimer

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.